[go: up one dir, main page]

WO2000052034A3 - Inhibitors of serine protease activity, methods and compositions for treatment of viral infections - Google Patents

Inhibitors of serine protease activity, methods and compositions for treatment of viral infections Download PDF

Info

Publication number
WO2000052034A3
WO2000052034A3 PCT/US2000/005558 US0005558W WO0052034A3 WO 2000052034 A3 WO2000052034 A3 WO 2000052034A3 US 0005558 W US0005558 W US 0005558W WO 0052034 A3 WO0052034 A3 WO 0052034A3
Authority
WO
WIPO (PCT)
Prior art keywords
serine protease
infection
viral infections
inhibitors
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/005558
Other languages
French (fr)
Other versions
WO2000052034A2 (en
Inventor
Leland Shapiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNIVERSITY TECHNOLOGY Corp, University of, Trustees of
TRUSTEES OF UNIVERSITY TECHNOL
Original Assignee
UNIVERSITY TECHNOLOGY Corp, University of, Trustees of
TRUSTEES OF UNIVERSITY TECHNOL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UNIVERSITY TECHNOLOGY Corp, University of, Trustees of, TRUSTEES OF UNIVERSITY TECHNOL filed Critical UNIVERSITY TECHNOLOGY Corp, University of, Trustees of
Priority to AU37191/00A priority Critical patent/AU3719100A/en
Publication of WO2000052034A2 publication Critical patent/WO2000052034A2/en
Publication of WO2000052034A3 publication Critical patent/WO2000052034A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A novel method of treating and preventing viral infection is provided. In particular a method of blocking viral infection facilitated by a serine proteolytic (SP) activity is disclosed, which consists of administering to a subject suffering or about to suffer from viral infection a therapeutically effective amount of a compound having a serine protease inhibitory or serpin activity. Among compounds are α1-antitrypsin (AAT), peptide derivatives from the carboxyterminal end of AAT, and man-made, synthetic compounds mimicking the action of such compounds. The preferred viral infections include retroviral infection such as human immunodeficiency virus (HIV) infection.
PCT/US2000/005558 1999-03-05 2000-03-03 Inhibitors of serine protease activity, methods and compositions for treatment of viral infections Ceased WO2000052034A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU37191/00A AU3719100A (en) 1999-03-05 2000-03-03 Inhibitors of serine protease activity, methods and compositions for treatment of viral infections

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12316799P 1999-03-05 1999-03-05
US60/123,167 1999-03-05
US13779599P 1999-06-03 1999-06-03
US60/137,795 1999-06-03

Publications (2)

Publication Number Publication Date
WO2000052034A2 WO2000052034A2 (en) 2000-09-08
WO2000052034A3 true WO2000052034A3 (en) 2001-01-11

Family

ID=26821301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/005558 Ceased WO2000052034A2 (en) 1999-03-05 2000-03-03 Inhibitors of serine protease activity, methods and compositions for treatment of viral infections

Country Status (2)

Country Link
AU (1) AU3719100A (en)
WO (1) WO2000052034A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849605B1 (en) 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
AU3731400A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
ATE377657T1 (en) * 2001-01-26 2007-11-15 Gen Hospital Corp SERPINE DRUGS FOR TREATING HIV INFECTION AND METHOD FOR USE THEREOF
US8563693B2 (en) 2001-01-26 2013-10-22 Acceleration Biopharmaceuticals, Inc. Method of treating human immunodeficiency virus infection in a mammal comprising administering heparin-activated antithrombin III
CA2536918A1 (en) 2003-08-26 2005-03-03 Leland Shapiro Compositions of, and methods for, alpha-1 antitrypsin fc fusion molecules
WO2007079312A2 (en) * 2005-12-02 2007-07-12 Regents Of The University Of Colorado Compositions and methods for treating actin-mediated medical conditions
BR112013002292A2 (en) 2010-09-14 2016-06-14 Hoffmann La Roche fusion polypeptide, protein complex, use and kit
EP2723370A4 (en) 2011-06-24 2015-06-03 Univ Colorado Regents COMPOSITIONS, METHODS, AND USES OF FUSION MOLECULES OF ALPHA-1 ANTITRYPSIN
US10478508B2 (en) 2012-01-10 2019-11-19 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
SG11201501036RA (en) 2012-08-23 2015-03-30 Alios Biopharma Inc Compounds for the treatment of paramoxyvirus viral infections
GB201820450D0 (en) 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532215A (en) * 1992-09-30 1996-07-02 Lezdey; John Antiviral compositions and method of use
WO1998024806A2 (en) * 1996-12-06 1998-06-11 Cortech, Inc. Substituted oxadiazole, thiadiazole and triazole serine protease inhibitors
WO1998046597A1 (en) * 1997-04-14 1998-10-22 Emory University Serine protease inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532215A (en) * 1992-09-30 1996-07-02 Lezdey; John Antiviral compositions and method of use
WO1998024806A2 (en) * 1996-12-06 1998-06-11 Cortech, Inc. Substituted oxadiazole, thiadiazole and triazole serine protease inhibitors
WO1998046597A1 (en) * 1997-04-14 1998-10-22 Emory University Serine protease inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDERSON ERIC D ET AL: "Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha-1-antitrypsin variant.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 33, 1993, pages 24887 - 24891, XP002145342, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU3719100A (en) 2000-09-21
WO2000052034A2 (en) 2000-09-08

Similar Documents

Publication Publication Date Title
WO2000051623A3 (en) Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
NO983688L (en) Serine protease inhibitors
FI912328A0 (en) PEPTIDFOERENING OCH DESS FRAMSTAELLNING.
EA199700221A1 (en) AMYNO ACID-SUBSTITUTED HYDROXYETHYLAMINOSULPHONAMIDE AS RETROVIRUS PROTEASE INHIBITORS
GEP20012415B (en) THF-Containing Sulfonamide Inhibitors of Aspartyl Protease
NO20075806L (en) Amino acid hydroxyethylaminosulfonamide retroviral protease inhibitors
NZ306026A (en) N-[2-hydroxy-3-sulphonyl-amino]-3-(hydrocarbylsulphonyl)hydrocarbyl-amide derivatives
DE69531944D1 (en) NEW HIV PROTEASE INHIBITORS
WO2000052034A3 (en) Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
NO974147L (en) Heterocycle carbonylamino acid hydroxyethylaminosulfonamide retroviral protease
NO983992L (en) Serine protease inhibitors
NO983991L (en) Serine protease inhibitors
MD960172A (en) 5,6-dihydropyrone derivatives as proteaze inhibitors and antiviral agents
DK1053012T3 (en) Pharmaceutical compositions comprising PEG asparaginase for the treatment of HIV infections
HK1041444A1 (en) Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections
NZ256246A (en) Serine leukocyte protease inhibitor, recombinant preparation thereof, and treatment of a retroviral infection
WO2000027418A3 (en) A method for treating tissue damaged from ischemia
MX9706912A (en) Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase